Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
230.59
+0.03 (0.01%)
At close: Jun 15, 2026, 4:00 PM EDT
229.88
-0.72 (-0.31%)
After-hours: Jun 15, 2026, 7:39 PM EDT
Jazz Pharmaceuticals Revenue
Jazz Pharmaceuticals had revenue of $1.07B in the quarter ending March 31, 2026, with 19.06% growth. This brings the company's revenue in the last twelve months to $4.44B, up 9.20% year-over-year. In the year 2025, Jazz Pharmaceuticals had annual revenue of $4.27B with 4.88% growth.
Revenue (ttm)
$4.44B
Revenue Growth
+9.20%
P/S Ratio
3.26
Revenue / Employee
$1,535,878
Employees
2,890
Market Cap
14.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.27B | 198.64M | 4.88% |
| Dec 31, 2024 | 4.07B | 234.75M | 6.12% |
| Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
| Dec 31, 2022 | 3.66B | 565.13M | 18.26% |
| Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
| Dec 31, 2020 | 2.36B | 201.81M | 9.34% |
| Dec 31, 2019 | 2.16B | 270.84M | 14.32% |
| Dec 31, 2018 | 1.89B | 272.23M | 16.82% |
| Dec 31, 2017 | 1.62B | 130.72M | 8.79% |
| Dec 31, 2016 | 1.49B | 163.17M | 12.32% |
| Dec 31, 2015 | 1.32B | 151.92M | 12.95% |
| Dec 31, 2014 | 1.17B | 300.46M | 34.44% |
| Dec 31, 2013 | 872.42M | 286.44M | 48.88% |
| Dec 31, 2012 | 585.98M | 313.70M | 115.21% |
| Dec 31, 2011 | 272.28M | 98.50M | 56.68% |
| Dec 31, 2010 | 173.78M | 45.33M | 35.29% |
| Dec 31, 2009 | 128.45M | 60.94M | 90.26% |
| Dec 31, 2008 | 67.51M | 2.21M | 3.39% |
| Dec 31, 2007 | 65.30M | 20.45M | 45.58% |
| Dec 31, 2006 | 44.86M | 23.41M | 109.20% |
| Dec 31, 2005 | 21.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genmab | 3.90B |
| BioMarin Pharmaceutical | 3.24B |
| Exelixis | 2.38B |
| Moderna | 2.23B |
| Madrigal Pharmaceuticals | 1.13B |
| Ionis Pharmaceuticals | 1.06B |
| Ascendis Pharma | 998.25M |
| Axsome Therapeutics | 708.24M |
JAZZ News
- 3 days ago - Jazz Pharmaceuticals lung cancer drug fails main trial goal - Reuters
- 3 days ago - Jazz Pharmaceuticals says Phase 3 LAGOON trial did not meet primary endpoint - TheFly
- 3 days ago - Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer - PRNewsWire
- 5 days ago - Jazz Pharmaceuticals price target raised to $307 from $281 at BofA - TheFly
- 6 days ago - Jazz Pharmaceuticals assumed with a Buy at Truist - TheFly
- 7 days ago - Jazz Pharmaceuticals Proxy statement: Proxy filing - Filings
- 7 days ago - Jazz Pharmaceuticals Proxy statement: Proxy filing - Filings
- 11 days ago - Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia - PRNewsWire